Drug Profile
Research programme: cyplasin glycoprotein - Bioxen
Alternative Names: Cyplasin; Cyplasin-SCLatest Information Update: 04 Apr 2011
Price :
$50
*
At a glance
- Originator Cyplasin Biomedical
- Developer Bioxen
- Class Glycoproteins; Recombinant proteins
- Mechanism of Action Actin modulators; Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma